Demand Fundamentals
|
Demand Technicals
Company Profile
ISTA Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets remedies for diseases and conditions of the eye in the United States. It offers products to treat allergy and serious disease of the eye- and therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. The company provides BROMDAY for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extractions- BEPREVE for ocular itching associated with allergic conjunctivitis- ISTALOL for the treatment of glaucoma- and VITRASE for use as a spreading agent. Its products under development include T-Pred for steroid responsive inflammation and allergic conjunctivitis- Strong steroid for ocular inflammation- REMURA for the treatment of dry eye syndrome- and BROMDAY (lower concentration) for postoperative inflammation and reduction of ocular pain. The company's products under development also comprise Bepotastine nasal and Bepotastine nasal combination for allergic rhinitis. In addition, it is developing iganidipine to enhance ocular nerve blood flow- prostaglandin, a formulation of latanoprost, for the treatment of glaucoma- and ecabet sodium for dry eyes. ISTA Pharmaceuticals, Inc. sells its products to drug wholesalers, retailers, and distributors, such as chain of drug stores, hospitals, clinics, and government agencies, as well as health maintenance organizations and other institutions. The company was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. ISTA Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Irvine, California.
|
